Opdivo (Nivolumab) Dosage


Medical Evidenceopdivo

Generic name : Nivolumab.

Trade name : Opdivo.

Manufacturer information :

Opdivo is manufactured by Bristol-Myers Squibb.

Opdivo FDA Approval :

Opdivo first approved December 22nd, 2014.

Opdivo Dosage form :

Injection: 40 mg/4 mL and 100 mg/10 mL solution in a single-use vial.

Opdivo Indications and Usage :


Indicated for unresectable or metastatic melanoma and disease progression following ipilimumab treatment and, if BRAF V600 mutation positive, a BRAF inhibitor.

Non-Small Cell Lung Cancer

Indicated for metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.


Opdivo (Nivolumab) availability in India

  • You could import this medicine against import permit on Patient Name.
  • Please contact ACT Lifesciences Private Limited for further information.